THE INSTITUTE FOR CANCER RESEARCH - TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER

PIID: 75N91022F00002Solicitation ID: TORFP 2022 E-02

Signed Date: Nov 24, 2025Effective Date: May 18, 2022End Date: Closes in 21 days

Award $

$1.2M

Vendor

THE INSTITUTE FOR CANCER RESEARCH

NAICS

541714

Signed Date

Nov 24, 2025

Key Details

Dollars Obligated

$1.2M

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

PHILADELPHIA, PA, 191112434, CD-PA-02

Description

TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER

Context & Analysis

On Nov 24, 2025, Department of Health and Human Services obligated $1,237,620 to THE INSTITUTE FOR CANCER RESEARCH for task order title: next generation gp130/il-6/stat3 inhibitors for the prevention of colitis-associated colorectal cancer. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in PHILADELPHIA, PA. The contract is scheduled through Nov 17, 2026 — approximately 1 month remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.